微血管阻力储备与心绞痛非阻塞性冠心病预后
该前瞻性多中心队列研究纳入553例心绞痛合并非阻塞性冠状动脉疾病患者,采用连续热稀释法测定微血管阻力储备(MRR),随访约27.5个月。结果显示MRR异常(CMD)与主要复合临床终点无显著相关,但低MRR与随访时心绞痛症状更重及临床相关改善更少相关。
要点
- MRR异常(<2.1)与主要复合临床终点无显著关联。
- 低MRR患者随访时SAQ汇总评分更差且改善比例更低。
- 连续热稀释法MRR可用于评估CMD,但预后预测价值有限。
核心结论
- 连续热稀释法测定的MRR评估的CMD与临床结局无关,但低MRR与随访时更差的心绞痛症状负担相关。
研究设计与样本
- 前瞻性多中心队列研究,纳入荷兰4个中心2020年7月至2025年6月连续ANOCA患者553例,平均随访27.5个月。
主要发现
- CMD(MRR<2.1)见于94例(17.0%)。
关键数值与推荐
- MRR异常(CMD)定义为<2.1,灰区为2.1至2.7,正常微血管功能为≥2.7。
临床怎么用
- 连续热稀释法MRR可用于评估ANOCA患者的冠状动脉微血管功能障碍,但异常MRR不提示短期临床事件风险增加,低MRR患者需关注随访时心绞痛症状改善情况。
局限性
- 研究为观察性队列,随访时间约27.5个月,症状改善分析样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Coronary microvascular dysfunction (CMD) is highly prevalent in patients with angina and nonobstructive coronary arteries (ANOCA). Microvascular resistance reserve (MRR) is a novel index to assess CMD independently of epicardial disease and driving pressures, but the long-term prognostic value of continuous thermodilution-derived MRR in patients with ANOCA is unknown. OBJECTIVE: To assess the prognostic value of continuous thermodilution-derived MRR and its association with clinical outcomes and symptom burden in patients with ANOCA. DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter cohort study within the Netherlands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT) included patients between July 2020 and June 2025 in 4 clinical centers in the Netherlands. Follow-up for clinical events and patient-reported symptoms was completed for up to 3 years. Clinical events were adjudicated by investigators blinded to CFT results. Consecutive patients with ANOCA who underwent continuous thermodilution were included. EXPOSURE: Abnormal MRR (CMD) was defined as less than 2.1, gray zone as 2.1 to 2.7, and normal microvascular function as 2.7 or greater. MAIN OUTCOMES AND MEASURES: The primary clinical outcome was a composite of all-cause death, acute coronary syndrome, stroke, clinically indicated revascularization, repeat angiography without intervention, and unplanned hospital admittance or emergency department visit due to angina or heart failure. Secondary outcomes included angina at baseline and follow-up. Symptoms were assessed using the patient-reported Seattle Angina Questionnaire (SAQ) scores. RESULTS: Among 553 included patients (mean [SD] age, 59.1 [9.6] years; 459 female [83.0%]) with a mean (SD) follow-up of 27.5 (16.1) months, CMD was observed in 94 patients (17.0%). The main composite outcome did not differ across the 3 MRR categories (18 of 94 patients with abnormal [19.1%] vs 21 of 98 patients with gray zone [21.4%] vs 76 of 361 patients with normal [21.1%] MRR; log-rank P = .85). Individual outcomes did not differ between groups. There was no overall longitudinal interaction between MRR and SAQ summary scores. While low MRR (abnormal vs normal groups) was not associated with an increased symptom burden at baseline, it was associated with worse angina at follow-up (mean [SD] SAQ summary score, 53.0 [16.7] vs 60.1 [16.6]; P = .04) and less clinically relevant improvement (9 of 30 patients [30.0%] vs 52 of 88 patients [59.1%]; P = .02). CONCLUSIONS AND RELEVANCE: In this study, CMD assessed by continuous thermodilution-derived MRR was not associated with clinical outcomes.
引用
- Yosofi B, Mechroubi A, de Vos A, et al. Microvascular Resistance Reserve and Outcomes in Angina and Nonobstructive Coronary Artery Disease. JAMA Cardiol. 2026. PMID: 42967827. doi:10.1001/jamacardio.2026.5270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。